Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Change in Inventory (2022 - 2025)

Zevra Therapeutics' Change in Inventory history spans 4 years, with the latest figure at $525000.0 for Q4 2025.

  • For Q4 2025, Change in Inventory fell 88.87% year-over-year to $525000.0; the TTM value through Dec 2025 reached $1.3 million, down 85.29%, while the annual FY2025 figure was $1.3 million, 85.29% down from the prior year.
  • Change in Inventory reached $525000.0 in Q4 2025 per ZVRA's latest filing, up from $194000.0 in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $4.7 million in Q4 2024 to a low of -$241000.0 in Q3 2022.
  • Average Change in Inventory over 4 years is $655066.7, with a median of $194000.0 recorded in 2025.
  • Peak YoY movement for Change in Inventory: tumbled 112.03% in 2023, then soared 29568.75% in 2024.
  • A 4-year view of Change in Inventory shows it stood at $133000.0 in 2022, then crashed by 112.03% to -$16000.0 in 2023, then skyrocketed by 29568.75% to $4.7 million in 2024, then crashed by 88.87% to $525000.0 in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Change in Inventory are $525000.0 (Q4 2025), $194000.0 (Q3 2025), and $381000.0 (Q2 2025).